About CoAxia
CoAxia is a company based in Maple Grove (United States) founded in 1999 was acquired by ZOLL AEDs in July 2013. CoAxia has raised $72.6 million across 4 funding rounds from investors including ZOLL AEDs, Canaan and Sofinnova. CoAxia operates in a competitive market with competitors including Rapid Medical, Cerus Endovascular, Anaconda Biomed, Oxford Endovascular and Fluid Biomed, among others.
- Headquarter Maple Grove, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Coaxia, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of CoAxia
CoAxia has successfully raised a total of $72.6M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $22.5 million completed in March 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CoAxia
CoAxia has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include ZOLL AEDs, Canaan and Sofinnova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked |
Investor details for CoAxia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CoAxia
Investment portfolio details for CoAxia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CoAxia
Detailed financials for CoAxia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Coaxia Comparisons
Peer comparison for CoAxia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CoAxia
CoAxia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rapid Medical, Cerus Endovascular, Anaconda Biomed, Oxford Endovascular and Fluid Biomed, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurovascular interventional devices including distal access catheters are developed.
|
|
| Locked | Locked | Locked |
Interventional neuroradiology devices are developed for minimally invasive aneurysm treatment.
|
|
| Locked | Locked | Locked |
Medical devices for mechanical thromboectomy and clot removal are developed.
|
|
| Locked | Locked | Locked |
Metallic mesh devices for brain aneurysms are developed.
|
|
| Locked | Locked | Locked |
A hybrid polymer-metal stent for brain aneurysms is developed.
|
Detailed competitors of CoAxia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Coaxia
Complete news archive for CoAxia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CoAxia
CoAxia was founded in 1999 and raised its 1st funding round 5 years after it was founded.
CoAxia is headquartered in Maple Grove, United States. It is registered at Maple Grove, Minnesota, United States.
CoAxia is a funded company, having raised a total of $72.6M across 4 funding rounds to date.
CoAxia was developing catheter-based perfusion augmentation therapies to improve outcomes for patients with cerebral ischemia. The core application for CoAxias catheter technology, under the trade names NeuroFlo and FloControl, involves the redistribution of blood flow from the lower extremities to support brain function during ischemia. Acquired by Zoll, an Asahi Kasei Group company in 2013.
CoAxia's top competitors include Rapid Medical, Fluid Biomed and Anaconda Biomed.
CoAxia has 7 investors. Key investors include ZOLL AEDs, Canaan, Sofinnova, Affinity Capital Management, and Johnson & Johnson Innovation – JJDC.